We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Capital One
COF
$136B
| $14.7M | 0.08% |
69,187
+36,982
| +115% | +$6.9M |
|
352
Pebblebrook Hotel Trust
PEB
$2.15B
| $14.7M | 0.08% |
1,468,035
-1,508,772
| -51% | -$14M |
|
353
MoonLake Immunotherapeutics
MLTX
$1.53B
| $14.7M | 0.08% |
310,602
+14,454
| +5% | +$589K |
|
354
Celanese
CE
$4.96B
| $14.6M | 0.08% |
+263,047
| New | +$13.1M |
|
355
Birkenstock
BIRK
$6.96B
| $14.4M | 0.08% |
292,831
-90,739
| -24% | -$4.66M |
|
356
Edgewise Therapeutics
EWTX
$4.81B
| $14.4M | 0.08% |
1,096,863
+54
| +0% | +$779 |
|
357
Comcast
CMCSA
$88.5B
| $14.4M | 0.08% |
402,854
-1,502,543
| -79% | -$52M |
|
358
UnitedHealth
UNH
$370B
| $14.3M | 0.08% |
45,869
-31,882
| -41% | -$12.2M |
|
359
T-Mobile US
TMUS
$190B
| $14M | 0.07% |
+58,695
| New | +$14.3M |
|
360
Deere & Co
DE
$167B
| $13.9M | 0.07% |
27,304
+5,905
| +28% | +$2.89M |
|
361
CrowdStrike
CRWD
$215B
| $13.7M | 0.07% |
107,768
-238,304
| -69% | -$25.8M |
|
|
HES
362
DELISTED
Hess
HES
| $13.7M | 0.07% |
98,990
-126,860
| -56% | -$17.1M |
|
|
FOLD
363
DELISTED
Amicus Therapeutics
FOLD
| $13.7M | 0.07% |
2,386,446
+2,085,616
| +693% | +$13.5M |
|
364
Intel
INTC
$509B
| $13.7M | 0.07% |
610,037
+4,293
| +0.7% | +$89K |
|
365
Maximus
MMS
$3.33B
| $13.7M | 0.07% |
+194,499
| New | +$13.7M |
|
366
Teladoc Health
TDOC
$1.22B
| $13.6M | 0.07% |
+1,560,442
| New | +$11.3M |
|
|
LINE
367
Lineage Inc
LINE
$9.54B
| $13.6M | 0.07% |
312,299
+272
| +0.1% | +$13.1K |
|
368
Lowe's Companies
LOW
$122B
| $13.4M | 0.07% |
60,542
+12,838
| +27% | +$2.87M |
|
369
Qualcomm
QCOM
$171B
| $13.4M | 0.07% |
84,185
+8,589
| +11% | +$1.26M |
|
370
Visteon
VC
$2.81B
| $13.3M | 0.07% |
+142,367
| New | +$11.7M |
|
371
Nokia
NOK
$55.4B
| $13.2M | 0.07% |
+2,554,141
| New | +$13.2M |
|
372
Dynatrace
DT
$13.3B
| $13.1M | 0.07% |
+237,999
| New | +$11.9M |
|
373
Beam Therapeutics
BEAM
$2.92B
| $13M | 0.07% |
761,498
+887
| +0.1% | +$15.4K |
|
374
Linde
LIN
$223B
| $12.9M | 0.07% |
27,475
-12,753
| -32% | -$5.82M |
|
375
Sociedad Química y Minera de Chile
SQM
$19.6B
| $12.6M | 0.07% |
358,117
+328,446
| +1,107% | +$11.2M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.